AbbVie announced positive Phase 3 results for etentamig, a T-cell engager targeting multiple myeloma. The company said etentamig cut the risk of disease progression or death by 60% compared with standard therapies, and the update supports further regulatory and development planning. The report also strengthens the competitive positioning of T-cell engager platforms in relapsed and refractory multiple myeloma, where sponsors are racing to expand use into earlier lines and deeper response settings. AbbVie did not disclose the full dataset in the provided summary, but the company framed the outcome as a meaningful efficacy signal alongside a continued focus on safety monitoring typical for T-cell engager programs. The Phase 3 headline may increase investor attention on how etentamig’s benefit-risk profile compares with other myeloma bispecifics and multi-specifics entering late-stage programs.